实用医学杂志2012，Vol.28Issue(20)：3367-3369,3.DOI:10.3969/j.issn.1006-5725.2012.20.018
同期放化疗加巩固化疗治疗Ⅲ～Ⅳa期鼻咽癌的临床分析
Concurrent chemoradiotherapy plus adjuvant chemotherapy for patients with nasopharyngeal carcinoma of stage Ⅲ and Ⅳ a
摘要
Abstract
Objective To observe the efficacy and toxicity of concurrent chemoradiotherapy plus adjuvant chemotherapy for nasopharyngeal carcinoma of stage III and VI a. Methods 48 patients with nasopharyngeal carcinoma of stage HI and IV a were administered with concurrent chemoradiotherapy plus adjuvant chemotherapy. The prescribed radiation regimen was 70 ～ 78 Gy/7 ~ 8week to nasopharynx, 60 ～70 Gy/6～ 7 week to cervical metastatic focus. The patients were treated with gemcitabine (gemcitabine group) or cisplatin (cisplatin group). Patients in gemcitabine group received concurrent gemcitabine (350 mg/m2 on day 1, 8, 15, 29, 36, 43) during radiation therapy, followed by gemcitabine (1 000 mg/m2 on day 1, 8, 15) every 4 weeks for 2 cycles. And patients in cisplatin group received concurrent cisplatin (350 mg/m2 on day 1, 22, 43) during radiation therapy, followed by cisplatin (80 mg/m2 on day 1) and fluorouracil (800 mg/m2 on days 1 to 5) every 4 weeks for 2 cycles. The adjuvant chemotherapy was administered in the 4th, 5th or 6th week after radiation therapy. Results The total response rates in the gemcitabine and cisplatin groups were 95.7% and 92% (P= 0.602). Toxicity was mainly shown as myelosuppression, gastrointestinal response, and oral mucositis, and other toxicity was relatively lighter. After symptomatic treatment, all the patients could tolerate these toxicities and finished the chemoradiotherapy. Conclusion Gemcitabine offers a satisfactory clinical activity and an acceptable safety profile in patients with nasopharyngeal carcinoma of stage IE and Via.关键词
鼻咽癌/放射治疗/化学治疗Key words
Nasopharynx/ Radiotherapy/ Chemotherapy引用本文复制引用
史建军,邵汛帆,邓敬锋..同期放化疗加巩固化疗治疗Ⅲ～Ⅳa期鼻咽癌的临床分析[J].实用医学杂志,2012,28(20):3367-3369,3.基金项目
广东省医学科研基金立项资助课题(编号:A2010279) （编号:A2010279）
